|
1
|
Armelao F and de Pretis G: Familial
colorectal cancer: A review. World J Gastroenterol. 20:9292–9298.
2014.PubMed/NCBI
|
|
2
|
James MI, Iwuji C, Irving G, Karmokar A,
Higgins JA, Griffin-Teal N, Thomas A, Greaves P, Cai H, Patel SR,
et al: Curcumin inhibits cancer stem cell phenotypes in ex vivo
models of colorectal liver metastases, and is clinically safe and
tolerable in combination with FOLFOX chemotherapy. Cancer Lett.
364:135–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lam AK, Chan SS and Leung M: Synchronous
colorectal cancer: Clinical, pathological and molecular
implications. World J Gastroenterol. 20:6815–6820. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Edwards BK, Noone AM, Mariotto AB, Simard
EP, Boscoe FP, Henley SJ, Jemal A, Cho H, Anderson RN, Kohler BA,
et al: Annual Report to the Nation on the status of cancer,
1975–2010, featuring prevalence of comorbidity and impact on
survival among persons with lung, colorectal, breast, or prostate
cancer. Cancer. 120:1290–1314. 2014. View Article : Google Scholar
|
|
5
|
Toden S, Okugawa Y, Jascur T, Wodarz D,
Komarova NL, Buhrmann C, Shakibaei M, Boland CR and Goel A:
Curcumin mediates chemosensitization to 5-fluorouracil through
miRNA-induced suppression of epithelial-to-mesenchymal transition
in chemoresistant colorectal cancer. Carcinogenesis. 36:355–367.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fan X, Zhang C, Liu DB, Yan J and Liang
HP: The clinical applications of curcumin: Current state and the
future. Curr Pharm Des. 19:2011–2031. 2013.
|
|
7
|
Wang J, Zhu R, Sun D, Sun X, Geng Z, Liu H
and Wang SL: Intracellular uptake of curcumin-loaded solid lipid
nanoparticles exhibit anti-inflammatory activities superior to
those of curcumin through the NF-kB signaling pathway. J Biomed
Nanotechnol. 11:403–415. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jin H, Qiao F, Wang Y, Xu Y and Shang Y:
Curcumin inhibits cell proliferation and induces apoptosis of human
non-small cell lung cancer cells through the upregulation of
miR-192-5p and suppression of PI3K/Akt signaling pathway. Oncol
Rep. 34:2782–2789. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sobolewski C, Muller F, Cerella C, Dicato
M and Diederich M: Celecoxib prevents curcumin-induced apoptosis in
a hematopoietic cancer cell model. Mol Carcinog. 54:999–1013. 2015.
View Article : Google Scholar
|
|
10
|
Liao H, Wang Z, Deng Z, Ren H and Li X:
Curcumin inhibits lung cancer invasion and metastasis by
attenuating GLUT1/MT1-MMP/MMP2 pathway. Int J Clin Exp Med.
8:8948–8957. 2015.PubMed/NCBI
|
|
11
|
Shehzad A, Qureshi M, Anwar MN and Lee YS:
Multifunctional curcumin mediate multitherapeutic effects. J Food
Sci. 82:2006–2015. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yallapu MM, Jaggi M and Chauhan SC:
Curcumin nano-medicine: A road to cancer therapeutics. Curr Pharm
Des. 19:1994–2010. 2013.
|
|
13
|
Zhu JY, Yang X, Chen Y, Jiang Y, Wang SJ,
Li Y, Wang XQ, Meng Y, Zhu MM, Ma X, et al: Curcumin suppresses
lung cancer stem cells via inhibiting Wnt/β-catenin and Sonic
Hedgehog pathways. Phytother Res. 31:680–688. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mukherjee S, Mazumdar M, Chakraborty S,
Manna A, Saha S, Khan P, Bhattacharjee P, Guha D, Adhikary A,
Mukhjerjee S, et al: Curcumin inhibits breast cancer stem cell
migration by amplifying the E-cadherin/β-catenin negative feedback
loop. Stem Cell Res Ther. 5:1162014. View
Article : Google Scholar
|
|
15
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
Biffoni M, Todaro M, Peschle C and De Maria R: Identification and
expansion of human colon-cancer-initiating cells. Nature.
445:111–115. 2007. View Article : Google Scholar
|
|
16
|
Taniguchi H, Moriya C, Igarashi H, Saitoh
A, Yamamoto H, Adachi Y and Imai K: Cancer stem cells in human
gastrointestinal cancer. Cancer Sci. 107:1556–1562. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bitarte N, Bandres E, Boni V, Zarate R,
Rodriguez J, Gonzalez-Huarriz M, Lopez I, Javier Sola J, Alonso MM,
Fortes P, et al: MicroRNA-451 is involved in the self-renewal,
tumorigenicity, and chemoresistance of colorectal cancer stem
cells. Stem Cells. 29:1661–1671. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu S, Wang X, Chen J and Chen Y: Autophagy
of cancer stem cells is involved with chemoresistance of colon
cancer cells. Biochem Biophys Res Commun. 434:898–903. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang Y, Wang G, Zhu D, Huang Y, Luo Y, Su
P, Chen X and Wang Q: Epithelial-mesenchymal transition and cancer
stem cell-like phenotype induced by Twist1 contribute to acquired
resistance to irinotecan in colon cancer. Int J Oncol. 51:515–524.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
22
|
Botchkina G: Colon cancer stem cells -
from basic to clinical application. Cancer Lett. 338:127–140. 2013.
View Article : Google Scholar
|
|
23
|
Elshamy WM and Duhé RJ: Overview: Cellular
plasticity, cancer stem cells and metastasis. Cancer Lett. 341:2–8.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yoshida GJ and Saya H: Therapeutic
strategies targeting cancer stem cells. Cancer Sci. 107:5–11. 2016.
View Article : Google Scholar :
|
|
25
|
Stavrovskaya AA and Stromskaya TP:
Transport proteins of the ABC family and multidrug resistance of
tumor cells. Biochemistry (Mosc). 73:592–604. 2008. View Article : Google Scholar
|
|
26
|
Dandawate PR, Subramaniam D, Jensen RA and
Anant S: Targeting cancer stem cells and signaling pathways by
phytochemicals: Novel approach for breast cancer therapy. Semin
Cancer Biol. 40–41:192–208. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chang TC, Yeh CT, Adebayo BO, Lin YC, Deng
L, Rao YK, Huang CC, Lee WH, Wu AT, Hsiao M, et al:
4-Acetylantroquinonol B inhibits colorectal cancer tumorigenesis
and suppresses cancer stem-like phenotype. Toxicol Appl Pharmacol.
288:258–268. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dalerba P, Dylla SJ, Park IK, Liu R, Wang
X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, et al:
Phenotypic characterization of human colorectal cancer stem cells.
Proc Natl Acad Sci USA. 104:10158–10163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sanders MA and Majumdar AP: Colon cancer
stem cells: Implications in carcinogenesis. Front Biosci.
16:1651–1662. 2011. View
Article : Google Scholar
|
|
30
|
Nautiyal J, Kanwar SS, Yu Y and Majumdar
AP: Combination of dasatinib and curcumin eliminates
chemo-resistant colon cancer cells. J Mol Signal. 6:72011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hong SP, Wen J, Bang S, Park S and Song
SY: CD44-positive cells are responsible for gemcitabine resistance
in pancreatic cancer cells. Int J Cancer. 125:2323–2331. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ma S: Biology and clinical implications of
CD133(+) liver cancer stem cells. Exp Cell Res. 319:126–132. 2013.
View Article : Google Scholar
|
|
33
|
Zhang SS, Han ZP, Jing YY, Tao SF, Li TJ,
Wang H, Wang Y, Li R, Yang Y, Zhao X, et al: CD133(+)CXCR4(+) colon
cancer cells exhibit metastatic potential and predict poor
prognosis of patients. BMC Med. 10:852012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cui S and Chang PY: Current understanding
concerning intestinal stem cells. World J Gastroenterol.
22:7099–7110. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Khan MI, Czarnecka AM, Helbrecht I,
Bartnik E, Lian F and Szczylik C: Current approaches in
identification and isolation of human renal cell carcinoma cancer
stem cells. Stem Cell Res Ther. 6:1782015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Abbaszadegan MR, Bagheri V, Razavi MS,
Momtazi AA, Sahebkar A and Gholamin M: Isolation, identification,
and characterization of cancer stem cells: A review. J Cell
Physiol. 232:2008–2018. 2017. View Article : Google Scholar
|
|
37
|
Cai J, Peng T, Wang J, Zhang J, Hu H, Tang
D, Chu C, Yang T and Liu H: Isolation, culture and identification
of choriocarcinoma stem-like cells from the human choriocarcinoma
cell-line JEG-3. Cell Physiol Biochem. 39:1421–1432. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Moghbeli M, Moghbeli F, Forghanifard MM
and Abbaszadegan MR: Cancer stem cell detection and isolation. Med
Oncol. 31:692014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shaheen S, Ahmed M, Lorenzi F and Nateri
AS: Spheroid-formation (colonosphere) assay for in iitro assessment
and expansion of stem cells in colon cancer. Stem Cell Rev.
12:492–499. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ning X, Du Y, Ben Q, Huang L, He X, Gong
Y, Gao J, Wu H, Man X, Jin J, et al: Bulk pancreatic cancer cells
can convert into cancer stem cells (CSCs) in vitro and 2 compounds
can target these CSCs. Cell Cycle. 15:403–412. 2016. View Article : Google Scholar
|
|
41
|
Kakarala M, Brenner DE, Korkaya H, Cheng
C, Tazi K, Ginestier C, Liu S, Dontu G and Wicha MS: Targeting
breast stem cells with the cancer preventive compounds curcumin and
piperine. Breast Cancer Res Treat. 122:777–785. 2010. View Article : Google Scholar
|
|
42
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pozzi V, Sartini D, Rocchetti R,
Santarelli A, Rubini C, Morganti S, Giuliante R, Calabrese S, Di
Ruscio G, Orlando F, et al: Identification and characterization of
cancer stem cells from head and neck squamous cell carcinoma cell
lines. Cell Physiol Biochem. 36:784–798. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Roy S, Lu K, Nayak MK, Bhuniya A, Ghosh T,
Kundu S, Ghosh S, Baral R, Dasgupta PS and Basu S: Activation of
D2 dopamine receptors in CD133+ve cancer stem cells in
non-small cell lung carcinoma inhibits proliferation, clonogenic
ability, and invasiveness of these cells. J Biol Chem. 292:435–445.
2017. View Article : Google Scholar
|
|
45
|
Taylor RC, Cullen SP and Martin SJ:
Apoptosis: Controlled demolition at the cellular level. Nat Rev Mol
Cell Biol. 9:231–241. 2008. View Article : Google Scholar
|
|
46
|
Gupta S, Kass GE, Szegezdi E and Joseph B:
The mitochondrial death pathway: A promising therapeutic target in
diseases. J Cell Mol Med. 13:1004–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang L, Huo X, Liao Y, Yang F, Gao L and
Cao L: Zeylenone, a naturally occurring cyclohexene oxide, inhibits
proliferation and induces apoptosis in cervical carcinoma cells via
PI3K/AKT/mTOR and MAPK/ERK pathways. Sci Rep. 7:16692017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Martinou JC and Youle RJ: Mitochondria in
apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev
Cell. 21:92–101. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Adan A, Alizada G, Kiraz Y, Baran Y and
Nalbant A: Flow cytometry: Basic principles and applications. Crit
Rev Biotechnol. 37:163–176. 2017. View Article : Google Scholar
|
|
50
|
Keyvani-Ghamsari S, Rabbani-Chadegani A,
Sargolzaei J and Shahhoseini M: Effect of irinotecan on HMGB1, MMP9
expression, cell cycle, and cell growth in breast cancer (MCF-7)
cells. Tumour Biol. 39:1010428317698354. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Rudolf E, John S and Cervinka M:
Irinotecan induces senescence and apoptosis in colonic cells in
vitro. Toxicol Lett. 214:1–8. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ogden A, Rida PC, Reid MD, Kucuk O and
Aneja R: Die-hard survivors: Heterogeneity in apoptotic thresholds
may underlie chemoresistance. Expert Rev Anticancer Ther.
15:277–281. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Spangle JM, Roberts TM and Zhao JJ: The
emerging role of PI3K/AKT-mediated epigenetic regulation in cancer.
Biochim Biophys Acta. 1868:123–131. 2017.PubMed/NCBI
|
|
54
|
Daaboul HE, Daher CF, Bodman-Smith K,
Taleb RI, Shebaby WN, Boulos J, Dagher C, Mroueh MA and El-Sibai M:
Antitumor activity of β-2-himachalen-6-ol in colon cancer is
mediated through its inhibition of the PI3K and MAPK pathways. Chem
Biol Interact. 275:162–170. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yu ST, Zhong Q, Chen RH, Han P, Li SB,
Zhang H, Yuan L, Xia TL, Zeng MS and Huang XM: CRLF1 promotes
malignant phenotypes of papillary thyroid carcinoma by activating
the MAPK/ERK and PI3K/AKT pathways. Cell Death Dis. 9:3712018.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhou Q, Chen J, Feng J, Xu Y, Zheng W and
Wang J: SOSTDC1 inhibits follicular thyroid cancer cell
proliferation, migration, and EMT via suppressing PI3K/Akt and
MAPK/Erk signaling pathways. Mol Cell Biochem. 435:87–95. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Serra V, Scaltriti M, Prudkin L, Eichhorn
PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M,
Rodriguez S, et al: PI3K inhibition results in enhanced HER
signaling and acquired ERK dependency in HER2-overexpressing breast
cancer. Oncogene. 30:2547–2557. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lin L, Liu Y, Li H, Li PK, Fuchs J,
Shibata H, Iwabuchi Y and Lin J: Targeting colon cancer stem cells
using a new curcumin analogue, GO-Y030. Br J Cancer. 105:212–220.
2011. View Article : Google Scholar : PubMed/NCBI
|
